Spruce Biosciences, Inc. Operating Cash Flow
Spruce Biosciences, Inc. (SPRB) reported Operating Cash Flow of -$30.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.12M.
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$8.73M.
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.46M.
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$5.32M.
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$33.33M.
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$55.96M.
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$33.27M.
- Spruce Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$41.68M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$30.85M 10-Q · filed 2026-08-12 | -$37.31M derived: sum of 3 quarters · filed 2026-08-12 | -$42.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$8.73M 10-Q · filed 2026-05-13 | -$15.19M derived: sum of 2 quarters · filed 2026-05-13 | -$20.50M derived: sum of 3 quarters · filed 2026-05-13 | -$29.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$6.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$11.77M derived: sum of 2 quarters · filed 2026-03-09 | -$20.60M derived: sum of 3 quarters · filed 2026-08-12 | -$33.33M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$5.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$14.14M derived: sum of 2 quarters · filed 2026-08-12 | -$26.87M 10-Q · filed 2025-11-10 | -$47.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$8.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$21.55M 10-Q · filed 2026-08-12 | -$42.23M derived: sum of 3 quarters · filed 2026-08-12 | -$51.45M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$12.73M 10-Q · filed 2026-05-13 | -$33.40M derived: sum of 2 quarters · filed 2026-05-13 | -$42.63M derived: sum of 3 quarters · filed 2026-05-13 | -$53.73M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$20.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$29.90M derived: sum of 2 quarters · filed 2026-03-09 | -$41.01M derived: sum of 3 quarters · filed 2026-03-09 | -$55.96M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$9.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$20.33M derived: sum of 2 quarters · filed 2025-11-10 | -$35.29M 10-Q · filed 2025-11-10 | -$46.50M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$11.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$26.06M 10-Q · filed 2025-08-14 | -$37.27M derived: sum of 3 quarters · filed 2025-08-14 | -$49.54M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$14.96M 10-Q · filed 2025-05-06 | -$26.17M derived: sum of 2 quarters · filed 2025-05-06 | -$38.44M derived: sum of 3 quarters · filed 2025-05-06 | -$36.44M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$23.48M derived: sum of 2 quarters · filed 2025-04-15 | -$21.48M derived: sum of 3 quarters · filed 2025-04-15 | -$33.27M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$12.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$10.28M derived: sum of 2 quarters · filed 2024-11-12 | -$22.07M 10-Q · filed 2024-11-12 | -$33.80M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$9.80M 10-Q · filed 2024-08-12 | -$21.54M derived: sum of 3 quarters · filed 2024-08-12 | -$30.11M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$11.79M 10-Q · filed 2024-05-13 | -$23.53M derived: sum of 2 quarters · filed 2024-05-13 | -$32.11M derived: sum of 3 quarters · filed 2024-05-13 | -$41.65M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$11.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$20.32M derived: sum of 2 quarters · filed 2024-03-18 | -$29.86M derived: sum of 3 quarters · filed 2024-03-18 | -$41.68M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$18.12M derived: sum of 2 quarters · filed 2023-11-13 | -$29.95M 10-Q · filed 2023-11-13 | -$39.74M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$9.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$21.37M 10-Q · filed 2023-08-14 | -$31.17M derived: sum of 3 quarters · filed 2023-08-14 | -$38.76M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$11.83M 10-Q · filed 2023-05-15 | -$21.63M derived: sum of 2 quarters · filed 2023-05-15 | -$29.22M derived: sum of 3 quarters · filed 2023-05-15 | -$38.92M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$17.40M derived: sum of 2 quarters · filed 2023-03-16 | -$27.09M derived: sum of 3 quarters · filed 2023-03-16 | -$35.88M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$7.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$17.29M derived: sum of 2 quarters · filed 2022-11-10 | -$26.08M 10-Q · filed 2022-11-10 | -$35.34M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$9.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$18.48M 10-Q · filed 2022-08-10 | -$27.75M derived: sum of 3 quarters · filed 2022-08-10 | -$35.34M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$8.79M 10-Q · filed 2022-05-11 | -$18.05M derived: sum of 2 quarters · filed 2022-05-11 | -$25.65M derived: sum of 3 quarters · filed 2022-05-11 | -$30.35M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$9.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$16.86M derived: sum of 2 quarters · filed 2022-03-14 | -$21.56M derived: sum of 3 quarters · filed 2022-03-14 | -$27.52M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$7.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$12.30M derived: sum of 2 quarters · filed 2021-11-15 | -$18.25M 10-Q · filed 2021-11-15 | -$21.16M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$10.66M 10-Q · filed 2021-08-10 | -$13.56M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | -$5.96M 10-Q · filed 2021-05-12 | -$8.86M derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$12.62M 10-K · filed 2021-03-22 | ||
| 2019-09-30 | -$9.71M 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |